Eris Lifesciences and Natco Pharma Collaborate to Introduce Semaglutide in Indian Market

Eris Lifesciences and Natco Pharma Partner to Commercialize Semaglutide in India

Eris Lifesciences, a leading pharmaceutical company in India, has entered into a strategic partnership with Natco Pharma to commercialize semaglutide in the country. This move marks a significant push by Eris to expand its presence in the fast-growing diabetes and metabolic-care market.

The partnership follows Natco Pharma's recent approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture generic semaglutide, paving the way for a planned launch in March 2026. With the expiration of Novo Nordisk's patents for Ozempic in March 2026, the market is expected to open up to 7-10 generic players, leading to a potential drop in monthly treatment costs from over Rs.10,000-Rs.12,000 to approximately Rs.3,000-Rs.4,000.

Semaglutide, a GLP-1 receptor agonist, is widely used in the treatment of Type 2 diabetes and weight management. India, with one of the world's largest and fastest-growing diabetic populations, is emerging as an important market for GLP-1 therapies. Eris, whose core franchise is built around chronic therapies and specialist-driven engagement, sees the launch as a logical extension of its diabetology portfolio.

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

The partnership brings together the commercial reach of Eris and the manufacturing and regulatory capabilities of Natco Pharma, which has built expertise in complex formulations. The arrangement will initially focus on Type 2 diabetes management but could expand with growing clinical use of GLP-1 therapies in broader metabolic health.

Eris, founded in 2007, is among India's top 20 pharma manufacturers. The company has generated over Rs.3,000 crore in branded formulations revenue in FY25 and has expanded into multiple specialties, including cardiovascular, dermatology, neurology, nephrology, oncology, and women's health. Over the past three years, Eris has invested roughly Rs.4,000 crore in expanding its geographic footprint and capabilities.